Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Alterations in Muscle Tone ll01:12

Alterations in Muscle Tone ll

Alterations in muscle tone are common manifestations of neurological disorders and reflect dysfunction within different nervous system regions. Spasticity, paratonia, and dystonia represent distinct forms of hypertonia, each with unique mechanisms, clinical features, and diagnostic importance.CharacteristicsSpasticity happens from upper motor neuron lesions and is characterized by velocity-dependent resistance to passive movement. Clinical features include:Exaggerated deep tendon reflexesClonus...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without GRN mutations.

Brain : a journal of neurology·2021
Same author

The contribution of behavioral features to caregiver burden in FTLD spectrum disorders.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2021
Same author

Posterior cortical atrophy phenotypic heterogeneity revealed by decoding <sup>18</sup>F-FDG-PET.

Brain communications·2021
Same author

The temporal onset of the core features in dementia with Lewy bodies.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2021
Same author

Rare PSAP Variants and Possible Interaction with GBA in REM Sleep Behavior Disorder.

Journal of Parkinson's disease·2021
Same author

Regional Brain Stiffness Analysis of Dementia with Lewy Bodies.

Journal of magnetic resonance imaging : JMRI·2021

Related Experiment Video

Updated: May 26, 2026

Technique for Intranasal Administration of &#945;-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

Progressive supranuclear palsy.

Bradley F Boeve1

  • 1Division of Behavioral Neurology, Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA. bboeve@mayo.edu

Parkinsonism & Related Disorders
|December 15, 2011
PubMed
Summary
This summary is machine-generated.

This review focuses on Progressive Supranuclear Palsy-Richardson's Syndrome (PSP-RS), detailing its clinical features, management, and the potential of new treatments. Early identification and trial participation are crucial for advancing PSP research.

More Related Videos

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Related Experiment Videos

Last Updated: May 26, 2026

Technique for Intranasal Administration of &#945;-Synuclein Aggregates
04:49

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

Area of Science:

  • Neurology
  • Neuroscience
  • Pathology

Background:

  • Progressive Supranuclear Palsy (PSP) is a rare neurodegenerative disease characterized by tauopathy.
  • PSP presents with diverse clinical syndromes, with PSP-Richardson's Syndrome (PSP-RS) being the most common variant.

Purpose of the Study:

  • To review the core clinical features, cognitive, motor, neuropsychiatric, and sleep manifestations of PSP-RS.
  • To discuss neuropsychological and neuroimaging findings associated with PSP-RS.
  • To explore current management strategies and emerging clinical trials for PSP.

Main Methods:

  • Literature review focusing on PSP-Richardson's Syndrome.
  • Analysis of clinical, neuropsychological, and neuroimaging data.
  • Discussion of therapeutic interventions and ongoing clinical trials.

Main Results:

  • PSP-RS has distinctive clinical, cognitive, motor, and neuropsychiatric features.
  • Neuroimaging plays a key role in diagnosing PSP-RS.
  • New clinical trials are investigating disease-modifying agents for tauopathies.

Conclusions:

  • Accurate identification of PSP-RS is essential for patient care and research.
  • The development of disease-modifying treatments offers hope for PSP patients.
  • Patient involvement in clinical trials is vital for advancing PSP research.